These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 36346100)

  • 61. First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer.
    Li L; Yang D; Min Y; Liao A; Zhao J; Jiang L; Dong X; Deng W; Yu H; Yu R; Zhao J; Shi A
    BMC Cancer; 2023 Apr; 23(1):318. PubMed ID: 37024843
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Research progress of anti-angiogenic drugs in the treatment of small cell lung cancer].
    Wang J; Li K
    Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):624-628. PubMed ID: 32867452
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Advances in immune checkpoint inhibitors therapy for small cell lung cancer.
    Li L; Liang Y; Yu M; Zhao L; Mei Q; Yu Y; Wang N; Zhang D; Wang Z; Jia Y; Kong F
    Cancer Med; 2023 May; 12(10):11097-11106. PubMed ID: 36880420
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Extensive-Stage Small-Cell Lung Cancer: Current Landscape and Future Prospects.
    Saida Y; Watanabe S; Kikuchi T
    Onco Targets Ther; 2023; 16():657-671. PubMed ID: 37551311
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evolving role of immunotherapy in small cell lung cancer.
    Barrows ED; Blackburn MJ; Liu SV
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):868-874. PubMed ID: 35192928
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer.
    Armstrong SA; Liu SV
    Curr Oncol Rep; 2020 Feb; 22(2):20. PubMed ID: 32034529
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Ando K; Manabe R; Kishino Y; Kusumoto S; Yamaoka T; Tanaka A; Ohmori T; Ohnishi T; Sagara H
    Curr Oncol; 2021 Feb; 28(2):1094-1113. PubMed ID: 33673470
    [TBL] [Abstract][Full Text] [Related]  

  • 68. PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications.
    Wang X; Zeng X; Li D; Zhu C; Guo X; Feng L; Yu Z
    Biomed Pharmacother; 2022 Sep; 153():113458. PubMed ID: 36076571
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Personalized Therapy of Small Cell Lung Cancer.
    Schneider BJ; Kalemkerian GP
    Adv Exp Med Biol; 2016; 890():149-74. PubMed ID: 26703804
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.
    Zugazagoitia J; Paz-Ares L
    J Clin Oncol; 2022 Feb; 40(6):671-680. PubMed ID: 34985925
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Targeted therapies for small cell lung cancer: Where do we stand?
    Arcaro A
    Crit Rev Oncol Hematol; 2015 Aug; 95(2):154-64. PubMed ID: 25800975
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lurbinectedin for the treatment of small cell lung cancer.
    Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
    Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
    Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
    BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Optimal drugs for second-line treatment of patients with small-cell lung cancer.
    Rossi A; Sacco PC; Sgambato A; Casaluce F; Santabarbara G; Palazzolo G; Maione P; Gridelli C
    Expert Opin Pharmacother; 2016; 17(7):969-76. PubMed ID: 26878692
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Drugs in development for small cell lung cancer.
    Serzan MT; Farid S; Liu SV
    J Thorac Dis; 2020 Oct; 12(10):6298-6307. PubMed ID: 33209468
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
    Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tackling the current dilemma of immunotherapy in extensive-stage small cell lung cancer: A promising strategy of combining with radiotherapy.
    Kang K; Wu Y; Yao Z; Lu Y
    Cancer Lett; 2023 Jul; 565():216239. PubMed ID: 37211066
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
    Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
    JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
    Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
    PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
    Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
    Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.